Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Current Deferred Revenue (2019 - 2022)

Lyell Immunopharma's Current Deferred Revenue history spans 4 years, with the latest figure at $11.2 million for Q3 2022.

  • For Q3 2022, Current Deferred Revenue rose 100.52% year-over-year to $11.2 million; the TTM value through Sep 2022 reached $11.2 million, up 100.52%, while the annual FY2021 figure was $5.0 million, 88.92% down from the prior year.
  • Current Deferred Revenue for Q3 2022 was $11.2 million at Lyell Immunopharma, down from $15.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $45.0 million in Q4 2019 and bottomed at $5.0 million in Q4 2021.
  • The 4-year median for Current Deferred Revenue is $9.7 million (2021), against an average of $17.7 million.
  • The largest annual shift saw Current Deferred Revenue crashed 88.92% in 2021 before it skyrocketed 100.52% in 2022.
  • A 4-year view of Current Deferred Revenue shows it stood at $45.0 million in 2019, then changed by 0.0% to $45.0 million in 2020, then plummeted by 88.92% to $5.0 million in 2021, then skyrocketed by 124.36% to $11.2 million in 2022.
  • Per Business Quant, the three most recent readings for LYEL's Current Deferred Revenue are $11.2 million (Q3 2022), $15.4 million (Q2 2022), and $6.2 million (Q1 2022).